MDSpire - Summary
Commentary & Perspectives

In Celebration of a Decades-Long Journey of Discovery and Innovation

On October 1, 2025, Benjamin L. Ebert, MD, PhD, celebrated the 1-year anniversary of being named President and Chief Executive Officer (CEO) of Dana-Farber Cancer Institute in Boston. He also holds th...

Share

Benjamin L. Ebert, MD, PhD, a fourth-generation physician, marks a year as President and CEO of Dana-Farber Cancer Institute, reflecting on a career dedicated to understanding and treating hematologic cancers. His journey began with a deep family legacy in medicine and evolved as he pursued an MD-PhD, contributing significantly to blood disorder research. Ebert's leadership is characterized by promoting collaboration in research and clinical practice, while advocating for the integration of artificial intelligence to expedite cancer drug development and enhance patient care.

Original Source(s)

In Celebration of a Decades-Long Journey of Discovery and Innovation

  • by Jo Cavallo

  • March 24, 2026

Related Content

Stanford Names Leader for Drug Development and Precision Oncology

Vivek Subbiah, MD, has been appointed as the inaugural associate director for drug development and precision oncology at the Stanford Cancer Institute, with a planned start date in spring 2026. In thi...

Integrative Oncology Scholars Program

Applications are now being accepted for the 2026 Integrative Oncology Scholars Program and Integrative Oncology Fellows Program at the University of Michigan in Ann Arbor (https://sites.google.com/vie...

FDA Approves Teclistamab and Daratumumab For Relapsed or Refractory Multiple Myeloma

On March 5, 2026, the U.S. Food and Drug Administration (FDA) approved teclistamab (Tecvayli) in combination with daratumumab hyaluronidase-fihj for the treatment of adult patients with relapsed or re...